Emergency Institute For Cardiovascular Diseases And Transplant
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The Emergency Institute For Cardiovascular Diseases And Transplant in Targu Mures is conducting clinical research focused on cardiovascular diseases, with a strong emphasis on cardiology and urgent heart care. The studies mainly explore acute myocardial infarction, heart failure, and related high-risk heart conditions, aiming to improve treatment effectiveness, reduce complications, and support better outcomes for patients.
- Research on early treatment approaches for acute myocardial infarction and suspected STEMI
- Studies evaluating new options for heart failure, including preserved and mildly reduced ejection fraction forms
- Trials addressing cardiovascular disease prevention, inflammation, and obesity-related heart risk
Across these trials, investigators are testing whether newer therapies can improve survival, lower the risk of hospitalization, and provide faster protection for people facing serious cardiac events.
Acute Myocardial Infarction and Emergency Cardiac Care
A major part of the research at this site centers on acute myocardial infarction and emergency response for patients with suspected or confirmed heart attack. These studies are designed to evaluate whether new treatments given very early can improve clinical outcomes and help prevent severe complications after an acute event.
- Trials in patients with suspected STEMI and ongoing ischemic chest pain
- Assessment of therapies intended for use before hospital arrival or at symptom onset
- Research focused on reducing early heart damage and improving short-term recovery
This work supports faster intervention strategies in emergency cardiology, with the goal of making acute heart attack care more effective for patients at highest risk.
Heart Failure Research
The site also has an active program in heart failure research, covering both reduced and preserved pumping function. These trials are exploring new ways to lower the risk of cardiovascular death, heart failure hospitalization, and urgent medical visits, while also addressing conditions such as obesity and systemic inflammation that can worsen the disease.
- Studies in heart failure with mildly reduced or preserved ejection fraction
- Research involving heart failure linked with obesity and systemic inflammation
- Evaluation of treatments aimed at improving long-term outcomes and symptom control
At the Emergency Institute For Cardiovascular Diseases And Transplant, this area of research reflects a broader effort to find better therapies for complex heart failure populations who remain at high risk despite standard care.
Cardiovascular Risk Reduction and Prevention
Another important research direction involves lowering the chance of first or recurrent major cardiovascular events. These studies are examining therapies for people with elevated risk factors such as lipoprotein(a) and prior acute myocardial infarction, with the aim of preventing future heart attacks and related complications.
- Prevention-focused studies in people at risk for a first major cardiovascular event
- Trials targeting recurrent myocardial infarction risk
- Research intended to improve long-term cardiovascular protection
This prevention-oriented work complements the site’s emergency and cardiology expertise by looking beyond immediate treatment to reduce future disease burden.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 13 therapeutic areas and 15 of 100 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 99 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 29 by active trials.
- 1AstraZeneca AB4active
lock +28 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB5trials
lock +10 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Emergency Institute For Cardiovascular Diseases And Transplant
lock Showing 1 of 65 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multicenter, placebo-controlled, randomized, double-blind, parallel-group comparison trial to investigate the efficacy and safety of brexpiprazole once-weekly (QW) formulation in patients with acute schizophrenia | Otsuka Pharmaceutical Co. Ltd. | Phase III | Recruiting | Jul 2024 | — |
IMP list
lock Showing 1 of 100 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bi 690517 | 3 | Unknown | 2024-10-18 | 2025-10-15 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.